These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 25174395)

  • 1. A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies.
    Althoff K; Beckers A; Bell E; Nortmeyer M; Thor T; Sprüssel A; Lindner S; De Preter K; Florin A; Heukamp LC; Klein-Hitpass L; Astrahantseff K; Kumps C; Speleman F; Eggert A; Westermann F; Schramm A; Schulte JH
    Oncogene; 2015 Jun; 34(26):3357-68. PubMed ID: 25174395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor development, growth characteristics and spectrum of genetic aberrations in the TH-MYCN mouse model of neuroblastoma.
    Rasmuson A; Segerström L; Nethander M; Finnman J; Elfman LH; Javanmardi N; Nilsson S; Johnsen JI; Martinsson T; Kogner P
    PLoS One; 2012; 7(12):e51297. PubMed ID: 23284678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
    Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
    Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells.
    Schulte JH; Lindner S; Bohrer A; Maurer J; De Preter K; Lefever S; Heukamp L; Schulte S; Molenaar J; Versteeg R; Thor T; Künkele A; Vandesompele J; Speleman F; Schorle H; Eggert A; Schramm A
    Oncogene; 2013 Feb; 32(8):1059-65. PubMed ID: 22484425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas.
    Huang R; Cheung NK; Vider J; Cheung IY; Gerald WL; Tickoo SK; Holland EC; Blasberg RG
    FASEB J; 2011 Dec; 25(12):4138-49. PubMed ID: 21856782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell lines from MYCN transgenic murine tumours reflect the molecular and biological characteristics of human neuroblastoma.
    Cheng AJ; Cheng NC; Ford J; Smith J; Murray JE; Flemming C; Lastowska M; Jackson MS; Hackett CS; Weiss WA; Marshall GM; Kees UR; Norris MD; Haber M
    Eur J Cancer; 2007 Jun; 43(9):1467-75. PubMed ID: 17449239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo.
    Chen Z; Lin Y; Barbieri E; Burlingame S; Hicks J; Ludwig A; Shohet JM
    Neoplasia; 2009 Aug; 11(8):753-62. PubMed ID: 19649205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma.
    Shohet JM; Ghosh R; Coarfa C; Ludwig A; Benham AL; Chen Z; Patterson DM; Barbieri E; Mestdagh P; Sikorski DN; Milosavljevic A; Kim ES; Gunaratne PH
    Cancer Res; 2011 Jun; 71(11):3841-51. PubMed ID: 21498633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification.
    Valentijn LJ; Koster J; Haneveld F; Aissa RA; van Sluis P; Broekmans ME; Molenaar JJ; van Nes J; Versteeg R
    Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19190-5. PubMed ID: 23091029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma.
    Dolman ME; Poon E; Ebus ME; den Hartog IJ; van Noesel CJ; Jamin Y; Hallsworth A; Robinson SP; Petrie K; Sparidans RW; Kok RJ; Versteeg R; Caron HN; Chesler L; Molenaar JJ
    Clin Cancer Res; 2015 Nov; 21(22):5100-9. PubMed ID: 26202950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroblastoma models for insights into tumorigenesis and new therapies.
    Kiyonari S; Kadomatsu K
    Expert Opin Drug Discov; 2015 Jan; 10(1):53-62. PubMed ID: 25345447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.
    Wyce A; Ganji G; Smitheman KN; Chung CW; Korenchuk S; Bai Y; Barbash O; Le B; Craggs PD; McCabe MT; Kennedy-Wilson KM; Sanchez LV; Gosmini RL; Parr N; McHugh CF; Dhanak D; Prinjha RK; Auger KR; Tummino PJ
    PLoS One; 2013; 8(8):e72967. PubMed ID: 24009722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma.
    Hogarty MD; Norris MD; Davis K; Liu X; Evageliou NF; Hayes CS; Pawel B; Guo R; Zhao H; Sekyere E; Keating J; Thomas W; Cheng NC; Murray J; Smith J; Sutton R; Venn N; London WB; Buxton A; Gilmour SK; Marshall GM; Haber M
    Cancer Res; 2008 Dec; 68(23):9735-45. PubMed ID: 19047152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NCYM, a Cis-antisense gene of MYCN, encodes a de novo evolved protein that inhibits GSK3β resulting in the stabilization of MYCN in human neuroblastomas.
    Suenaga Y; Islam SM; Alagu J; Kaneko Y; Kato M; Tanaka Y; Kawana H; Hossain S; Matsumoto D; Yamamoto M; Shoji W; Itami M; Shibata T; Nakamura Y; Ohira M; Haraguchi S; Takatori A; Nakagawara A
    PLoS Genet; 2014 Jan; 10(1):e1003996. PubMed ID: 24391509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma.
    Schramm A; Köster J; Marschall T; Martin M; Schwermer M; Fielitz K; Büchel G; Barann M; Esser D; Rosenstiel P; Rahmann S; Eggert A; Schulte JH
    Int J Cancer; 2013 Feb; 132(3):E106-15. PubMed ID: 22907398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of mir-21, which is up-regulated during MYCN knockdown-mediated differentiation, does not prevent differentiation of neuroblastoma cells.
    Buechner J; Henriksen JR; Haug BH; Tømte E; Flaegstad T; Einvik C
    Differentiation; 2011 Jan; 81(1):25-34. PubMed ID: 20980091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma.
    Rounbehler RJ; Li W; Hall MA; Yang C; Fallahi M; Cleveland JL
    Cancer Res; 2009 Jan; 69(2):547-53. PubMed ID: 19147568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 is a direct transcriptional target of MYCN in neuroblastoma.
    Chen L; Iraci N; Gherardi S; Gamble LD; Wood KM; Perini G; Lunec J; Tweddle DA
    Cancer Res; 2010 Feb; 70(4):1377-88. PubMed ID: 20145147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MDM2 as MYCN transcriptional target: implications for neuroblastoma pathogenesis.
    Slack A; Lozano G; Shohet JM
    Cancer Lett; 2005 Oct; 228(1-2):21-7. PubMed ID: 15927364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors.
    Hackett CS; Hodgson JG; Law ME; Fridlyand J; Osoegawa K; de Jong PJ; Nowak NJ; Pinkel D; Albertson DG; Jain A; Jenkins R; Gray JW; Weiss WA
    Cancer Res; 2003 Sep; 63(17):5266-73. PubMed ID: 14500357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.